CEACAM5 and neoplasm: Preclinical studies targeting MC38-CEA, 4T1, and LLC (lung) tumors explored the ability of N803 to activate tumor-specific T cells in combination with Ad-(CEA or Twist1), OX40, and GITR agonists, and the indoleamine 2,3-dioxygenase (IDO) inhibitor epacadostat [57].